RECOMMENDATIONS AND GUIDANCE ON
HEPATITIS C VIRUS SELF-TESTING
July 2021
Web Annex B. Declaration of interests for the Guideline Development Group,
Observers and Peer Reviewers
Recommendations and guidance on hepatitis C virus self-testing. Web Annex B. Declaration of interests for the Guideline Development Group, Observers and Peer Reviewers
ISBN 978-92-4-003115-9 (electronic version)
© World Health Organization 2021
Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).
Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.
Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization
(http://www.wipo.int/amc/en/mediation/rules/).
Suggested citation. Web Annex B. Declaration of interests for the Guideline Development Group, Observers and Peer Reviewers. In: Recommendations and guidance on hepatitis C virus self-testing. Geneva: World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO.
Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.
Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third- party-owned component in the work rests solely with the user.
General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by WHO to verify the information contained in this publication.
However, the published material is being distributed without warranty of any kind, either expressed or implied.
The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.
This publication forms part of the WHO guideline entitled Recommendations and guidance on hepatitis C
virus self-testing. It is being made publicly available for transparency purposes and information, in accordancewith the WHO handbook for guideline development, 2nd edition (2014).
Contents
1. Guideline Development Group members (n=18) ... 1
2. Guideline Development Group meeting observers (n=8 ) ... 3
3. Guideline Development Group peer reviewers (n=49) ... 4
1
1. Guideline Development Group members (n=18)
GDG composition
Gender Percentage Region Percentage
M (12) 67.0% AFRO 11.0%
F (6) 33.0% AMRO 22.0%
EURO 22.0%
EMRO 6.0%
SEARO 28.0%
WPRO 11.0%
Summary of GDG declarations of interest
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Tanya Applegate,
Kirby Inst, Australia
Yes 0 0 0 0 0 0 0 0
Nadia Badran, SIDC, Lebanon
Yes 0 0 0 0 0 0 0 0
Ajeet Singh Bhadoria, independent consultant, India
Yes 0 0 0 0 0 0 0 0
Meghan DiCarlo, FHI 360, USA
Yes 0 0 0 0 0 0 0 0
Mauro Guarinieri, INPUD,
Switzerland
Yes 0 0 0 0 0 0 0 0
Saeed Sadiq Hamid, Aga Khan Univ, Pakistan
Yes 0 0 0 0 0 0 0 0
2
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Irsan Hassan,
MoH, Indonesia
Yes 0 0 0 0 2b. Research
support, Gilead, other, USD1500;
ended in 2016
0 0 0
Karin Hatzold, PSI, South Africa
Yes 0 0 0 0 0 0 0 0
Cary James, Hepatitis Alliance, UK
Yes 0 0 0 0 0 0 0 0
Anushiya Karunanithy, Malaysian AIDS Council, Malaysia
Yes 0 0 0 0 0 0 0 0
Giten Khwairakpam, Treat Asia / amfAR, Thailand
Yes 0 0 0 0 0 0 0 0
Karine Lacombe, St. Antoine Hospital, France
Yes 0 0 0 0 0 0 0 0
Segundo Leon, Univ of Peru, Peru
Yes 0 0 0 0 0 0 0 0
José Boullosa Alonso Neto, MoH, Brazil
Yes 0 0 0 0 0 0 0 0
Midnight Pookasetwattana, APCOM, Thailand
Yes 0 0 0 0 0 0 0 0
Christian Ramers, CHAI, USA
Yes 0 0 1b.
Technical advisor, CHAI, self,
$50,000 (current) 1b. National Liver Disease
2a. Community- based testing grant, FOCUS program, Gilead Sciences, research unit, $163,896 (2019) 2a. Pragmatic clinical trial,
2b. HCV speakers bureau (therapeutics), Gilead Sciences, self, $10,000 (current) 2b. HCV speakers bureau (therapeutics),
0 0 0
3
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Advisory
Board, Gilead Sciences, self, $5,000 (current) 1b. AbbVie, self, $5,000 (current)
Mobile HCV treatment of PWID, STAT program, Gilead Sciences, research unit, $637,500 (current)*
AbbVie, self,
$10,000 (current)
Janvier Serumondo, MoH, Rwanda
Yes 0 0 0 0 0 0 0 0
Ernst Wisse, Médecins du Monde, France
Yes 0 0 0 0 0 0 0 0
* Further interrogation revealed it was an investigator-initiated study and funder had no role in the design or conduct of the research. The GDG member was not the principal investigator on this study.
Based on review of declarations of interest, declared interests were determined to be non-significant. All GDG members had full participation rights and there were no additional restrictions recommended.
2. Guideline Development Group meeting observers (n=8)
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Lee Abdelfidil,
Global Fund, Switzerland
Yes 0 0 0 0 0 0 0 0
Paige Armstrong, CDC, USA
Yes 0 0 0 0 0 0 0 0
Nathan Furukawa, CDC, USA
Yes 0 0 0 0 0 0 0 0
4
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Elena Ivanova,
FIND, Switzerland
Yes 0 0 0 0 0 0 0 0
Sonjelle Shilton, FIND,
Switzerland
Yes 0 0 0 0 0 0 0 0
Indri Sukmaputri, MoH, Indonesia
Yes 0 0 0 0 0 0 0 0
Josephine Walker, Bristol, UK
Yes 0 0 0 2a. Gilead
Sciences, co- investigator on a research grant,
£169231 (2019- 2022)
0 0 0 0
Vincent Wong, USAID, USA
Yes 1a. USAID
regular salary, not disclosed (current)
0 0 0 0 0 0 0
Based on review of declarations of interest, no specific restrictions were recommended.
3. Guideline Development Group peer reviewers (n=32)
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Paige Armstrong,
CDC, USA
Yes 0 0 0 0 0 0 0 0
Taryn Barker, CIFF, UK
Yes 0 0 0 0 0 0 0 0
Elkin Bermudez, Independent consultant, Switzerland
Yes 1b. FIND,
$15,000 (2020)
0 0 0 0 0 0 0
5
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Yap Boum,
Epicentre MSF, Cameroon
Yes 0 0 0 0 0 0 0 0
Colleen Daniels, Harm Reduction International, UK
Yes 0 0 0 0 0 0 0 0
Maka Gogia, Harm Reduction Network, Georgia
Yes 0 0 0 0 0 0 0 0
Kimberly Green, PATH, Viet Nam
Yes 1b. Employment
and research, PATH, USAID- funded KP health programs (2014-present)
0 0 0 0 0 0 0
Asha Hedge, PATH, India
Yes 0 0 0 0 0 0 0 0
Moses Kumwenda, LSHTM, Malawi
Yes 1b. Consulting / technical or other advisor
0 0 0 0 0 0 0
Jeffrey Lazarus, ISG Global, Denmark
Yes 0 0 0 2a. ISG research
unit has received grants from Gilead Sciences.
2b. JVL has received speaker fees from AbbVie, Gilead and MSD.
0 0 0 0
Mohammad Majam, WITS RHI, South Africa
Yes 0 0 0 2a. Research
funding, FIND,
$490,000 (current)
0 0 0 0
Guillermo Martínez Pérez, Univ of Zaragosa, Spain
Yes 0 0 0 0 0 0 0 0
6
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Francesco Negro,
EASL, UNIGE, Italy
Yes 0 0 0 0 0 0 0 0
Jean Njab, independent consultant, Nigeria
Yes 0 0 0 0 0 0 0 0
Daniel Nitkin, INPUD, Kyrgyzstan
Yes 0 0 0 0 0 0 0 0
Chase Perfect, Coalition Plus, Switzerland
Yes 1a. Policy
officer working on access to HCV testing and treatment, funded by Unitaid; no public positions on HCVST (project ending in spring 2021) Organization has supported uptake of HIVST
0 0 0 0 0 0 0
Muhammad Radzi Abu Hassan, MoH, Malaysia
Yes 0 0 0 0 0 0 0 0
Danvic Rosadino, Love Yourself, Philippines
Yes 0 0 0 0 0 0 0 0
Sanjay Sarin, FIND, India
Yes 1b. Consulting / technical or other advisor
0 0 2a. Research
support, including grants,
collaborations, sponsorships, and other funding
0 0 0 0
7
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Mark Sonderup,
Univ of Cape Town, South Africa
Yes 0 0 0 0 0 0 0 0
Christian Stillson, CHAI, USA
Yes 0 0 0 0 0 0 0 0
Ketevan Stvilia, MoH, GF Programme Manager, Georgia
Yes 1b. Current position as GF Programme Manager, funded by GF
0 0 0 2b. Member of
research team on HCV diagnostics for PWID, funded by FIND/Unitaid (2018-2020)
0 0 0
Geoffery Tassi, MoH, Uganda
Yes 0 0 0 0 0 0 0 0
Katayoun Tayeri, MoH, Lebanon
Yes 0 0 0 0 0 0 0 0
Thiago Torres, Fiocruz, Brazil
Yes 0 0 0 0 0 0 0 0
Joseph Tucker, University of North Carolina at Chapel Hill, USA
Yes 0 0 0 0 0 0 0 0
Peris Urasa, MoH, Tanzania
Yes 0 0 0 0 0 0 0 0
John Ward, Coalition for Global Hepatitis Elimination, USA
Yes 0 0 0 Abbott, AbbVie,
Cepheid, Gilead Sciences, Merck, Parco, Roche, Siemens Zydus- Cadila, AASLD, EASL, USG, Task Force for Global Health for general support of the Coalition for Global Hepatitis Elimination (current)
0 0 0 0
8
1.
Name / Institution / Country
2.
COU completed
3.
Employment &
consulting
4.
Advisory boards 5.
Consulting fees
6.
Research support (grants / funding)
7.
Research support (non-monetary)
8.
Investments / business interests
9.
Public statements / positions
10.
Tobacco / Tobacco products Carolyn Wester,
CDC, USA
Yes 0 0 0 0 0 0 0 0
